China In Vitro Diagnostic (IVD) Industry Report, 2019-2025
  • Jun.2019
  • Hard Copy
  • USD $3,400
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $3,200
  • Code: ZLC085
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,800
  • Hard Copy + Single User License
  • USD $3,600

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IVD market has burgeoned due to robust demand over the years, with its size approximating RMB57.6 billion in 2018, an annualized jump of 19.3%.

Reagents now prevail in the Chinese IVD industry, sweeping over 70% of the total value of the industry. In the country, IVD reagents mainly include those for immunological, biochemical and molecular diagnostics, among which the first two kinds of diagnosis reagents are the mainstay of the industry, seizing a combined more than 60% shares.


In China, world-renowned big names such as Roche, Siemens, Abbott and Thermo Fisher are the main players in the high-end IVD market; local companies including Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shanghai Kehua Bio-Engineering Co., Ltd., Maccura Biotechnology Co., Ltd., Autobio Diagnostics Co., Ltd., Dirui Industrial Co., Ltd., Beijing Leadman Biochemistry Co., Ltd., MedicalSystem Biotechnology Co., Ltd. and Sinocare Inc., have gained a firm foothold in the low- and mid-end markets.

China has issued industrial policies to shore up local Chinese IVD companies since 2011, setting the stage for homemade products to replace the imported. Lower price and favorable policies are a boon for Chinese companies to break the monopoly of their foreign peers.

China’s IVD industry will head toward the following directions in the years to come:

1. Factors such as population aging, two-child policy and higher health budget will be conducive to the rising demand for IVD;
2. Frequent mergers and acquisitions will make the market more concentrated;
3. High-end immunological diagnostics, molecular diagnostics and point-of-care testing (POCT) will be three major trends.

The report highlights the following:
20120114.gifChina IVD industry (development status, market size, market structure, competitive pattern and development trends);
20120114.gifChina IVD market segments (development status, competitive pattern and development trends);
20120114.gifChina IVD downstream sectors;
20120114.gif6 foreign and 24 Chinese IVD companies (operation, gross margin, IVD business, development strategy, etc.).

1 Overview
1.1 Definition
1.2 Classification

2 China In Vitro Diagnostic Industry
2.1 Development Status
2.2 Market Size
2.3 Market Structure
2.4 Competitive Pattern
2.5 Development Trends 
2.5.1 Aging of Population Spurs IVD Industry
2.5.2 Higher Healthcare Expenditures are a Boon for IVD Industry
2.5.3 Government Backs IVD Industry
2.5.4 High-end Immunological Diagnostics, Molecular Diagnostics and POCT will be Three Major Trends
2.5.5 Related Companies Flock to Capital Market for Further Development 
2.5.6 Implementation of Two-child Policy Fuels IVD Industry
2.5.7 Frequent Mergers and Acquisitions are Likely to Make IVD Market More Concentrated 

3 China IVD Market Segments
3.1 Companion Diagnostics
3.1.1 Development Status
3.1.2 Market Structure
3.1.3 Market Size
3.1.4 Growth Drivers
3.1.5 Competitive Pattern
3.2 Immunological Diagnostics
3.2.1 Development Status
3.2.2 Competitive Pattern
3.2.3 Development Trends
3.3 Molecular Diagnostics
3.3.1 Development Status
3.3.2 Competitive Pattern
3.3.3 Development Trends
3.4 Biochemical Diagnostics
3.4.1 Development Status
3.4.2 Competitive Pattern
3.4.3 Development Trends
3.5 POCT
3.5.1 Development Status
3.5.2 Competitive Pattern
3.5.3 Development Trends

4 China IVD Downstream Sectors
4.1 Healthcare Sector
4.1.1 Number of Medical Institutions
4.1.2 Medical Services
4.1.3 Medical Income
4.2 Independent Clinical Laboratory Sector
4.2.1 Development Status
4.2.2 Market Size
4.2.3 Competitive Pattern
4.2.4 Development Trends

5 Major Foreign Companies
5.1 Roche
5.1.1 Profile
5.1.2 Operation
5.1.3 In Vitro Diagnostics Business
5.1.4 Development in China
5.2 Siemens
5.2.1 Profile
5.2.2 Operation
5.2.3 In Vitro Diagnostics Business
5.2.4 Development in China
5.3 Abbott
5.3.1 Profile
5.3.2 Operation
5.3.3 In Vitro Diagnostics Business
5.3.4 Development in China
5.4 Thermo Fisher
5.4.1 Profile
5.4.2 Operation
5.4.3 In Vitro Diagnostics Business
5.4.4 Development in China
5.5 Danaher
5.5.1 Profile
5.5.2 Operation
5.5.3 In Vitro Diagnostics Business
5.5.4 Development in China
5.6 Sysmex
5.6.1 Profile
5.6.2 Operation
5.6.3 In Vitro Diagnostics Business
5.6.4 Development in China

6 Major Chinese Companies 
6.1 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Gross Margin
6.1.4 In Vitro Diagnostics Business
6.1.5 Development Strategy
6.2 Autobio Diagnostics Co., Ltd.
6.2.1 Profile
6.2.2 Operation
6.2.3 Gross Margin
6.2.4 In Vitro Diagnostics Business
6.2.5 Development Strategy
6.3 Beijing Strong Biotechnologies, Inc.
6.3.1 Profile
6.3.2 Operation
6.3.3 Gross Margin
6.3.4 In Vitro Diagnostics Business
6.3.5 Development Strategy
6.4 MedicalSystem Biotechnology Co., Ltd.
6.4.1 Profile
6.4.2 Operation
6.4.3 Gross Margin
6.4.4 In Vitro Diagnostics Business
6.4.5 Development Strategy
6.5 DAAN Gene Co., Ltd. of Sun Yat-sen University
6.5.1 Profile
6.5.2 Operation
6.5.3 Gross Margin
6.5.4 In Vitro Diagnostics Business
6.5.5 Development Strategy
6.6 Beijing Leadman Biochemistry Co., Ltd.
6.6.1 Profile
6.6.2 Operation
6.6.3 Gross Margin
6.6.4 In Vitro Diagnostics Business
6.6.5 Development Strategy
6.7 Sinocare Inc.
6.7.1 Profile
6.7.2 Operation
6.7.3 Gross Margin
6.7.4 In Vitro Diagnostics Business
6.7.5 Development Strategy
6.8 Shanghai Kehua Bio-Engineering Co., Ltd.
6.8.1 Profile
6.8.2 Operation
6.8.3 Gross Margin
6.8.4 In Vitro Diagnostics Business
6.8.5 Development Strategy
6.9 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
6.9.1 Profile
6.9.2 Operation
6.9.3 Gross Margin
6.9.4 In Vitro Diagnostics Business
6.9.5 Development Strategy
6.10 Livzon Pharmaceutical Group Inc.
6.10.1 Profile
6.10.2 Operation
6.10.3 Gross Margin
6.10.4 In Vitro Diagnostics Business
6.10.5 Development Strategy
6.11 Maccura Biotechnology Co., Ltd.
6.11.1 Profile
6.11.2 Operation
6.11.3 Gross Margin
6.11.4 In Vitro Diagnostics Business
6.11.5 Development Strategy
6.12 Guangzhou Wondfo Biotech Co., Ltd. 
6.12.1 Profile
6.12.2 Operation
6.12.3 Gross Margin
6.12.4 In Vitro Diagnostics Business
6.12.5 Development Strategy
6.13 Biosino Bio-Technology and Science Inc.
6.13.1 Profile
6.13.2 Operation
6.13.3 Gross Margin
6.13.4 In Vitro Diagnostics Business
6.13.5 Development Strategy
6.14 Jiangsu Bioperfectus Technologies Co., Ltd.
6.14.1 Profile
6.14.2 Operation
6.14.3 Gross Margin
6.14.4 In Vitro Diagnostics Business
6.14.5 Development Strategy
6.15 Zhejiang Orient Gene Biotech Co., Ltd.
6.15.1 Profile
6.15.2 Operation
6.15.3 Gross Margin
6.15.4 In Vitro Diagnostics Business
6.15.5 Development Strategy
6.16 HOB Biotech Group Suzhou Co., Ltd.
6.16.1 Profile
6.16.2 Operation
6.16.3 Gross Margin 
6.16.4 In Vitro Diagnostics Business
6.16.5 Development Strategy
6.17 Lifotronic Technology Co., Ltd.
6.17.1 Profile
6.17.2 Operation
6.17.3 Gross Margin
6.17.4 In Vitro Diagnostics Business
6.17.5 Development Strategy
6.18 Hotgen Biotech Co., Ltd.
6.18.1 Profile
6.18.2 Operation
6.18.3 Gross Margin
6.18.4 In Vitro Diagnostics Business
6.18.5 Development Strategy
6.19 Dirui Industrial Co., Ltd.
6.19.1 Profile
6.19.2 Operation
6.19.3 Gross Margin
6.19.4 In Vitro Diagnostics Business
6.19.5 Development Strategy
6.20 Getein Biotech, Inc.
6.20.1 Profile
6.20.2 Operation
6.20.3 Gross Margin
6.20.4 In Vitro Diagnostics Business
6.20.5 Development Strategy
6.21 Guangdong Hybribio Biotech Co., Ltd.
6.21.1 Profile
6.21.2 Operation
6.21.3 Gross Margin
6.21.4 In Vitro Diagnostics Business
6.21.5 Development Strategy
6.22 Beijing Bohui Innovation Biotechnology Co., Ltd.
6.22.1 Profile
6.22.2 Operation
6.22.3 Gross Margin
6.22.4 In Vitro Diagnostics Business
6.22.5 Development Strategy
6.23 Edan Instruments, Inc.
6.23.1 Profile
6.23.2 Operation
6.23.3 Gross Margin
6.23.4 In Vitro Diagnostics Business
6.23.5 Development Strategy
6.24 Wuhan Easy Diagnosis Biomedicine Co., Ltd.
6.24.1 Profile
6.24.2 Operation
6.24.3 Gross Margin
6.24.4 In Vitro Diagnostics Business
6.24.5 Development Strategy
Classification of In Vitro Diagnosis
Classification of In Vitro Diagnostic Instruments
Classification of In Vitro Diagnostic Reagents
Global In Vitro Diagnostic Market Size, 2015-2018
Medical Instrument Market Size in China, 2013-2018
Development History of In Vitro Diagnostic Industry in China
In Vitro Diagnostic Market Size in China, 2009-2018
In Vitro Diagnostic Market Size in China, 2018-2025E
In Vitro Diagnostic Market Structure in China (by Type), 2018
In Vitro Diagnostic Market Structure in China (by Product), 2018
Competition Pattern of Diagnostic Reagent Industry in China
In Vitro Diagnostic Product Layout of Chinese In Vitro Diagnostic Companies
IVD Revenue of Major Diagnostic Reagent Enterprises in China, 2014-2018
IVD Market Share of Major Diagnostic Reagent Enterprises in China, 2014-2018
Population Aged over 60 in China, 2009-2018
Total Health Expenditure in China, 2010-2018
Policies on In Vitro Diagnostic Industry in China, 2012-2018
Development Prospects of In Vitro Diagnostic Market Segments in China
Development History of Companion Diagnostic Reagent Kits
Joint Launch History of Targeted Drugs and their Companion Diagnostic
Companion Diagnostic Reagents Approved by FDA for Marketing 
Number of Companion Diagnostic Products Approved in the US (by Technology) 
Market Share of Companion Diagnostic Reagents in the US (by Technology), 2018
Number of Companion Diagnostic Products Approved in the US (by Target) 
Number of Companion Diagnostic Products Approved in the US (by Indication) 
Market Share of Companion Diagnostic Reagents in the US (by Indication), 2018
Global Companion Diagnostic Market Size, 2016-2025E 
Companion Diagnostic Market Size in China, 2016-2025E 
FDA's Regulatory History of Companion Diagnostic Reagents
Companion Diagnostic Coverage of Major Insurance Companies in the US
Merits and Demerits of Different Companion Diagnostic Business Models 
Comparison between Five Immunodiagnostic Technologies
Chemiluminescence Diagnostic Market Share in China, 2018
Chemiluminescence Diagnosis VS Enzyme-linked Immunodiagnosis
Comparison between Main Technologies Applied to Molecular Diagnostics
Market Share of Molecular Diagnostic Enterprises in China, 2018
NGS-based Tumor Diagnostic Reagent Kits of Local Chinese Enterprises in Special Approval Procedures for Innovative Medical Instruments
Financing Cases in China’s Gene Sequencing Industry, 2017-2018
Categories of Biochemical Diagnostic Reagents
Categories of Biochemical Diagnostic Systems in China
Market Share of Biochemical Diagnostic Enterprises in China, 2018
Applied Scenarios and Fields of POCT Products
Comparison between POCT and Clinical Laboratory Diagnosis
Market Share of POCT Enterprises in China, 2018
Layout of Chinese Enterprises in POCT
Potential POCT Market Size in China
Number of Medical and Health Institutions in China, 2015-2019
Number of Hospitals in China, 2009-2019
Number of Hospitals in China by Economic Type, 2009-2019
Clinic Visits of Medical Institutions in China, 2015-2019
Clinic Visits of Hospitals in China, 2009-2019
Clinic Visits of Hospitals in China by Economic Type, 2012-2019
Total Revenue of Medical and Health Institutions in China, 2010-2018
Total Revenue of Medical and Health Institutions in China, 2018-2025E
Total Revenue of Hospitals in China, 2009-2018
Comparison of Independent Clinical Laboratory Market Penetration between China, Europe, America and Japan, 2018
Comparison of Diagnostic Item Quantity among Various Medical Institutions
Independent Clinical Laboratory Market Size in China, 2010-2018
Number of Independent Clinical Laboratories in China, 2007-2018
Independent Clinical Laboratory Revenue of Main Independent Clinical Laboratory Enterprises in China, 2014-2018
Marker Share of Independent Clinical Laboratory Enterprises in China, 2018
Comprehensive Comparison between Leading Independent Clinical Laboratory Enterprises in China, 2018
Independent Clinical Laboratory Market Size and YoY Growth in China, 2018-2025E
Policies on Public Hospital Reform in China, 2015-2019
Number of Private Hospitals and YoY Growth in China, 2009-2018
Clinic Visits of Private Hospitals in China, 2012-2018
Population Aged over 60 in China, 2009-2018
Market Share of Kingmed Diagnostics, 2014-2018
Revenue and Net Income of Roche, 2013-2018
Revenue Structure of Roche by Product, 2013-2018
IVD Revenue of Roche, 2013-2018
Revenue and Net Income of Siemens, 2013-2018
Revenue Structure of Siemens by Product, 2013-2018
IVD Revenue of Siemens, 2013-2018
Revenue and Net Income of Abbott, 2013-2018
Revenue Structure of Abbott by Product, 2013-2018
IVD Revenue of Abbott, 2013-2018
Revenue and Net Income of Thermo Fisher, 2013-2018
Revenue Structure of Thermo Fisher by Product, 2013-2018
IVD Revenue of Thermo Fisher, 2013-2018
Revenue and Net Income of Danaher, 2013-2018
Revenue Structure of Danaher by Product, 2013-2018
IVD Revenue of Danaher, 2013-2018
Revenue and Net Income of Sysmex, 2013-2018
Revenue Structure of Sysmex by Product, 2013-2018
IVD Revenue of Sysmex, 2013-2018
Revenue and Net Income of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
Revenue Structure of Shenzhen Mindray Bio-Medical Electronics by Product, 2013-2018
Gross Margin of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
IVD Revenue of Shenzhen Mindray Bio-Medical Electronics, 2013-2018
Revenue and Net Income of Autobio Diagnostics, 2013-2018
Revenue Structure of Autobio Diagnostics by Product, 2013-2018
Gross Margin of Autobio Diagnostics, 2013-2018
IVD Revenue of Autobio Diagnostics, 2013-2018
Revenue and Net Income of Beijing Strong Biotechnologies, 2013-2018
Revenue Structure of Beijing Strong Biotechnologies by Product, 2013-2018
Gross Margin of Beijing Strong Biotechnologies, 2013-2018
IVD Revenue of Beijing Strong Biotechnologies, 2013-2018
Revenue and Net Income of MedicalSystem Biotechnology, 2013-2018
Revenue Structure of MedicalSystem Biotechnology by Product, 2013-2018
Gross Margin of MedicalSystem Biotechnology, 2013-2018
IVD Revenue of MedicalSystem Biotechnology, 2013-2018
Revenue and Net Income of DAAN Gene, 2013-2018
Revenue Structure of DAAN Gene by Product, 2013-2018
Gross Margin of DAAN Gene, 2013-2018
IVD Revenue of DAAN Gene, 2013-2018
Revenue and Net Income of Beijing Leadman Biochemistry, 2013-2018
Revenue Structure of Beijing Leadman Biochemistry by Product, 2013-2018
Gross Margin of Beijing Leadman Biochemistry, 2013-2018
IVD Revenue of Beijing Leadman Biochemistry, 2013-2018
Revenue and Net Income of Sinocare, 2013-2018
Revenue Structure of Sinocare by Product, 2013-2018
Gross Margin of Sinocare, 2013-2018
IVD Revenue of Sinocare, 2013-2018
Revenue and Net Income of Shanghai Kehua Bio-Engineering, 2013-2018
Revenue Structure of Shanghai Kehua Bio-Engineering by Product, 2013-2018
Gross Margin of Shanghai Kehua Bio-Engineering, 2013-2018
IVD Revenue of Shanghai Kehua Bio-Engineering, 2013-2018
Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2018
Revenue Structure of Shanghai Fosun Pharmaceutical by Product, 2013-2018
Gross Margin of Shanghai Fosun Pharmaceutical, 2013-2018
IVD Revenue of Shanghai Fosun Pharmaceutical, 2013-2018
Revenue and Net Income of Livzon Pharmaceutical Group, 2013-2018
Revenue Structure of Livzon Pharmaceutical Group by Product, 2013-2018
Gross Margin of Livzon Pharmaceutical Group, 2013-2018
IVD Revenue of Livzon Pharmaceutical Group, 2013-2018
Revenue and Net Income of Maccura Biotechnology, 2013-2018
Revenue Structure of Maccura Biotechnology by Product, 2013-2018
Gross Margin of Maccura Biotechnology, 2013-2018
IVD Revenue of Maccura Biotechnology, 2013-2018
Revenue and Net Income of Guangzhou Wondfo Biotech, 2013-2018
Revenue Structure of Guangzhou Wondfo Biotech by Product, 2013-2018
Gross Margin of Guangzhou Wondfo Biotech, 2013-2018
IVD Revenue of Guangzhou Wondfo Biotech, 2013-2018
Revenue and Net Income of Biosino Bio-Technology and Science, 2013-2018
Revenue Structure of Biosino Bio-Technology and Science by Product, 2013-2018
Gross Margin of Biosino Bio-Technology and Science, 2013-2018
IVD Revenue of Biosino Bio-Technology and Science, 2013-2018
Revenue and Net Income of Jiangsu Bioperfectus Technologies, 2013-2018
Revenue Structure of Jiangsu Bioperfectus Technologies by Product, 2013-2018
Gross Margin of Jiangsu Bioperfectus Technologies, 2013-2018
IVD Revenue of Jiangsu Bioperfectus Technologies, 2013-2018
Revenue and Net Income of Zhejiang Orient Gene Biotech, 2013-2018
Revenue Structure of Zhejiang Orient Gene Biotech by Product, 2013-2018
Gross Margin of Zhejiang Orient Gene Biotech, 2013-2018
IVD Revenue of Zhejiang Orient Gene Biotech, 2013-2018
Revenue and Net Income of HOB Biotech Group Suzhou, 2013-2018
Revenue Structure of HOB Biotech Group Suzhou by Product, 2013-2018
Gross Margin of HOB Biotech Group Suzhou, 2013-2018
IVD Revenue of HOB Biotech Group Suzhou, 2013-2018
Revenue and Net Income of Lifotronic Technology, 2013-2018
Revenue Structure of Lifotronic Technology by Product, 2013-2018
Gross Margin of Lifotronic Technology, 2013-2018
IVD Revenue of Lifotronic Technology, 2013-2018
Revenue and Net Income of Hotgen Biotech, 2013-2018
Revenue Structure of Hotgen Biotech by Product, 2013-2018
Gross Margin of Hotgen Biotech, 2013-2018
IVD Revenue of Hotgen Biotech, 2013-2018
Revenue and Net Income of Dirui Industrial, 2013-2018
Revenue Structure of Dirui Industrial by Product, 2013-2018
Gross Margin of Dirui Industrial, 2013-2018
IVD Revenue of Dirui Industrial, 2013-2018
Revenue and Net Income of Getein Biotech, 2013-2018
Revenue Structure of Getein Biotech by Product, 2013-2018
Gross Margin of Getein Biotech, 2013-2018
IVD Revenue of Getein Biotech, 2013-2018
Revenue and Net Income of Guangdong Hybribio Biotech, 2013-2018
Revenue Structure of Guangdong Hybribio Biotech by Product, 2013-2018
Gross Margin of Guangdong Hybribio Biotech, 2013-2018
IVD Revenue of Guangdong Hybribio Biotech, 2013-2018
Revenue and Net Income of Beijing Bohui Innovation Biotechnology, 2013-2018
Revenue Structure of Beijing Bohui Innovation Biotechnology by Product, 2013-2018
Gross Margin of Beijing Bohui Innovation Biotechnology, 2013-2018
IVD Revenue of Beijing Bohui Innovation Biotechnology, 2013-2018
Revenue and Net Income of Edan Instruments, 2013-2018
Revenue Structure of Edan Instruments by Product, 2013-2018
Gross Margin of Edan Instruments, 2013-2018
IVD Revenue of Edan Instruments, 2013-2018
Revenue and Net Income of Wuhan Easy Diagnosis Biomedicine, 2013-2018
Revenue Structure of Wuhan Easy Diagnosis Biomedicine by Product, 2013-2018
Gross Margin of Wuhan Easy Diagnosis Biomedicine, 2013-2018
IVD Revenue of Wuhan Easy Diagnosis Biomedicine, 2013-2018

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号